Call for Abstract

4th International Conference on Vascular Dementia, will be organized around the theme “Integrating Recent Discoveries and Interpreting Vascular Dementia Research for Better Health”

Vascular Dementia 2016 is comprised of 24 tracks and 148 sessions designed to offer comprehensive sessions that address current issues in Vascular Dementia 2016.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Alcohol-related dementia is a broad term currently preferred among medical professionals.

Many experts use the terms alcohol (or alcoholic) dementia to describe a specific form of ARD, characterized by impaired executive function (planning, thinking, and judgment).

Another form of ARD is known as wet brain (Wernicke-Korsakoff syndrome), characterized by short term memory loss and thiamine (vitamin B1) deficiency. ARD patients often have symptoms of both forms, i.e. impaired ability to plan, apathy, and memory loss. ARD may occur with other forms of dementia (mixed dementia). The diagnosis of ARD is widely recognized but rarely applied, due to a lack of specific diagnostic criteria.

  • Track 1-1Wernicke-Korsakoff Syndrome
  • Track 1-2Causes of alcoholic dementia
  • Track 1-3Alcoholic dementia test
  • Track 1-4Treatment for alcoholic dementia
  • Track 1-5Advances in the prevention of alcoholic dementia

The mainstay of management of vascular dementia is the prevention of new strokes. This includes administering antiplatelet drugs and controlling major vascular risk factors.

Neuroprotective drugs such as nimodipine, propentofylline, and posatirelin are currently under study and may be useful for vascular dementia.

  • Track 5-1Omentum in the treatment of vascular dementia
  • Track 5-2Cholinisterase inhibitors
  • Track 5-3Impact of treatment with N-Acetylcysteine
  • Track 5-4Oral redox polymer therapeutics
  • Track 5-5Snoezellen and Multi sensory stimulation
  • Track 5-6Effect of thioctic and enantiomers
  • Track 5-7Role of phospholipids
  • Track 5-8Effects of brain afobazole

Rapidly progressive dementias (RPDs) are neurological conditions that develop subacutely over weeks to months, or rarely acutely over days. In contrast to most dementing conditions that take years to progress to death, RPD can be quickly fatal. It is critical to evaluate the RPD patient without delay, usually in a hospital setting, as they may have a treatable condition. 

  • Track 6-1Progressive dementias
  • Track 6-2Degenerative dementias
  • Track 6-3Prion diseases
  • Track 6-4Chronic degenerative dementias
  • Track 6-5Autoimmune encephalopathies
  • Track 6-6Delirium and dementia
  • Track 6-7Advances in sudden dementia research

Almost 40 per cent of people over the age of 65 experience some form of memory loss. When there is no underlying medical condition causing this memory loss, it is known as "age-associated memory impairment," which is considered a part of the normal aging process.

Brain diseases like Alzheimer’s disease and other dementias are different.

Age-associated memory impairment and dementia can be told apart in a number of ways.

  • Track 7-1Brain ageing and dementia
  • Track 7-2Risk factors of cognitive decline
  • Track 7-3Normal ageing and dementia
  • Track 7-4Neuro-anatomical changes in ageing
  • Track 7-5Functional imaging test
  • Track 7-6Advances of research in ageing and dementia

National Plan to Address Alzheimer’s Disease, a national effort to expand research in Alzheimer’s and related dementias prevention and treatment and to move the most promising drugs from discovery into clinical trials.

The Plan aims to prevent and effectively treat Alzheimer’s and related dementias by 2025. Its foundation is the 2011 National Alzheimer’s Project Act (NAPA), which was developed to create and maintain a national strategy to overcome the disease.

  • Track 8-1Future development of therapies
  • Track 8-2Aerobic exercise program
  • Track 8-3Research in induced pluripotent stem cells
  • Track 8-4Researches in amyloid and tau proteins
  • Track 8-5Digital engagement for people with dementia

Admiral Nurses are specialist dementia nurses who give much-needed practical and emotional support to family carers, as well as the person with dementia.

To offer support to families throughout their experience of dementia that is tailored to their individual needs and challenges.

To provide families with the knowledge to understand the condition and its effects, the skills and tools to improve communication, and provide emotional and psychological support to help family carers carry on caring for their family member.

  • Track 9-1Primary mental health care and nursing
  • Track 9-2Assessment and evaluation of mental health
  • Track 9-3Cognitive behavioral therapy and family therapy in nursing
  • Track 9-4Stress and emotional treatment studies and outcomes

Vascular disease is mainly caused by hardening of the arteries (atherosclerosis) due to a thickening of the artery lining from fatty deposits or plaques (atheroma).

Vascular disease may manifest acutely when thrombi, emboli, or acute trauma compromises perfusion. Thrombosis are often of an athermanous nature and occur in the lower extremities more frequently than in the upper extremities. Multiple factors predispose patients for thrombosis. These factors include sepsis, hypotension, low cardiac output, aneurysms, aortic dissection, bypass grafts, and underlying atherosclerotic narrowing of the arterial lumen.

  • Track 10-1Peripheral artery disease
  • Track 10-2Aneurysm
  • Track 10-3Amyloid cascade and tau pathology
  • Track 10-4Vascular pathology in aging brain
  • Track 10-5Protein trafficking and synaptic pathology
  • Track 10-6White matter pathology in vascular cogitive disease
  • Track 10-7Hippocampal pathology in aged
  • Track 10-8Retinal pathology in susac syndrome
  • Track 10-9Cerebral amyloid angiopathy

Diagnosing dementia is often difficult, particularly in the early stages. The GP is the first person to consult. The GP may then refer the person being diagnosed to a specialist such as a consultant.

Assessments can include conversations with the person being diagnosed and those close to them, a physical examination, memory tests and/or brain scans.

The Mini Mental State Examination (MMSE) is the most commonly used test for complaints of memory problems or when a diagnosis of dementia is being considered.

  • Track 11-1 Mini Mental State Examination
  • Track 11-2Blood tests for dementia
  • Track 11-3Dementia brain scans
  • Track 11-4Cognitive testing
  • Track 11-5Neuropsychological testing
  • Track 11-6Radiological tests
  • Track 11-7Brain imaging techniques

Dementia is the loss of cognitive functioning, which means the loss of the ability to think, remember, or reason, as well as behavioural abilities, to such an extent that it interferes with a person’s daily life and activities.

Vascular dementia and vascular cognitive impairment (VCI) are caused by injuries to the vessels supplying blood to the brain. These disorders can be caused by brain damage from multiple strokes or any injury to the small vessels carrying blood to the brain.

  • Track 12-1Stroke-related dementia
  • Track 12-2Post stroke dementia
  • Track 12-3Subcortical vascular dementia
  • Track 12-4Mixed dementia
  • Track 12-5Multi-infarct dementia
  • Track 12-6Young onset dementia
  • Track 12-7Sleep and dementia
  • Track 12-8White matter and dementia
  • Track 12-9Computational/ Mathematical modelling of dementia
  • Track 12-10Parkinson dementia

Frontotemporal dementia (frontotemporal lobar degeneration) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain — the areas generally associated with personality, behavior and language.

In frontotemporal dementia, portions of these lobes atrophy or shrink. Signs and symptoms vary, depending upon the portion of the brain affected. Some people with frontotemporal dementia undergo dramatic changes in their personality and become socially inappropriate, impulsive or emotionally indifferent, while others lose the ability to use language.

  • Track 13-1Frotal lobed dementia
  • Track 13-2Frontal lobed dementia stage
  • Track 13-3Frontal lobed dementia life expectancies
  • Track 13-4Frontal dementia test
  • Track 13-5Advances in frontal dementia research
  • Track 13-6Frontal dementia treatment

Lewy bodies are also found in other brain disorders, including Alzheimer's disease and Parkinson's disease dementia.

Many people with Parkinson's eventually develop problems with thinking and reasoning, and many people with DLB experience movement symptoms, such as hunched posture, rigid muscles, a shuffling walk and trouble initiating movement.

  • Track 14-1Cognitive problems
  • Track 14-2Movement disorders
  • Track 14-3Depression and lewy body dementia
  • Track 14-4Lewy body dementia test
  • Track 14-5Disruption of the autonomic nervous system
  • Track 14-6Early stages of lewy body dementia
  • Track 14-7End stage of lew body dementia
  • Track 14-8Advances in lewy body dementia treatment

Progressive dementia, which is dementia that gets worse with time, is the most common type. Five stages of progressive dementia have been outlined. They are part of the Clinical Dementia Rating (CDR), which professionals use to evaluate the progression of symptoms in patients with dementia.

The five stages describe a patient’s ability to perform in six different areas of cognition and functioning: orientation, memory, judgment, home and hobbies, personal care, and community.

  • Track 15-1Early dementia
  • Track 15-2Moderate dementia
  • Track 15-3Advanced dementia
  • Track 15-4Test of dementia stages
  • Track 15-5Advances in research of dementia stages

A range of tests and diagnostic procedures is needed to diagnose dementia, but there are several that are fairly commonly used to diagnose dementia.

These tests for dementia are mainly tests of mental abilities, blood tests and brain scans.

Tests can help the doctor learn whether dementia is caused by a treatable condition. Even for those dementias that cannot be reversed, knowing the type of dementia a person has can help the doctor prescribe medicines or other treatments that may improve mood and behavior and help the family.

  • Track 16-1Diagnosis of vascular dementia
  • Track 16-2Vascular dementia test
  • Track 16-3Neuroimaging
  • Track 16-4Biomarkers
  • Track 16-5Amyloid and tau imaging
  • Track 16-6Diffusion kurtosis imaging
  • Track 16-7Radiology
  • Track 16-8Hippocampal diffusion tensor imaging
  • Track 16-9Positron emission tomography
  • Track 16-10EEG and brain mapping
  • Track 16-11MR spectroscopy
  • Track 16-12Advances in the field of imaging
  • Track 16-13Role of neurosonsology

Vascular dementia is the second most common type of dementia (after Alzheimer's disease), affecting around 150,000 people in the UK.

The word dementia describes a set of symptoms that can include memory loss and difficulties with thinking, problem-solving or language. In vascular dementia, these symptoms occur when the brain is damaged because of problems with the supply of blood to the brain. 

  • Track 17-1Vascular dementia prognosis
  • Track 17-2Senile dementia
  • Track 17-3Senelity
  • Track 17-4Cognitive impairment
  • Track 17-5Advances in vascular dementia cognitive impairment treatment

Dementia with Lewy bodies (DLB), also known under a variety of other names including Lewy body dementia (LBD), diffuse Lewy body disease, cortical Lewy body disease, and senile dementia of Lewy type, is a type of dementia closely associated with Parkinson's disease.

It is characterized anatomically by the presence of Lewy bodies, clumps of alpha-synuclein and ubiquitin protein in neurons, detectable in post mortem brain histology. Lewy body dementia affects 1.3 million individuals in the United States alone.

  • Track 18-1Lewy body disorders
  • Track 18-2Muscle rigidity
  • Track 18-3Neurotransmitter abnormalities
  • Track 18-4Symptoms of lewy body dementia
  • Track 18-5Causes of lewy body dementia
  • Track 18-6Management of lewy body dementia
  • Track 18-7Advances in lewy body dementia research

Dementia is a group of symptoms that can occur as a result of some diseases that damage the brain (examples of such diseases: Alzheimer’s Disease, strokes, Fronto-Temporal Dementia, Lewy Body Dementia, etc).

The abilities of persons with dementia decline in many ways. This affects them and everyone around them–family members, friends, colleagues, etc.

  • Track 19-1Pediatric dementia
  • Track 19-2Nutritional factors and dementia
  • Track 19-3Malnutrition, undernutrition and obesity in dementia
  • Track 19-4Palliative care in vascular dementia
  • Track 19-5Natural remedies for the treatment
  • Track 19-6Advanced researches for dementia care
  • Track 19-7Advances in neuropharmacology in brain protection and recovery
  • Track 19-8Role of dietry nitrates
  • Track 19-9Music Therapy in Dementia
  • Track 19-10Advance Care Planning
  • Track 19-11End of life care and grief in dementia
  • Track 19-12Admiral Nursing
  • Track 19-13Antipsychotic medications
  • Track 19-14Betrothal therapy

Severe Demnetia is the fifth stage of dementia is the most severe. At this point your loved one cannot function at all without help. They have experienced extreme memory loss. Additionally, they have no understanding of orientation in time or geography.

It is almost impossible to go out and engage in everyday activities, even with assistance. Function in the home is completely gone and help is required for attending to personal needs.

  • Track 20-1Stages in severe dementia
  • Track 20-2Advances in severe dementia research
  • Track 20-3Severe dementia causes
  • Track 20-4Severe dementia test
  • Track 20-5Treatment of severe dementia
  • Track 20-6Advanced therapeutics for severe dementia

Mild cognitive impairment (MCI) is a term used to describe a condition involving problems with cognitive function (their mental abilities such as thinking, knowing and remembering).

People with MCI often have difficulties with day-to-day memory, but such problems are not bad enough to be defined as dementia.

  • Track 21-1Mild cognitive impairment
  • Track 21-2Advances in mild dementia research
  • Track 21-3Causes of mild dementia
  • Track 21-4Mild dementia test
  • Track 21-5Diagnosis of mild dementia

Frontotemporal dementia (frontotemporal lobar degeneration) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain, the areas generally associated with personality, behavior and language.

In frontotemporal dementia, portions of these lobes atrophy or shrink. Signs and symptoms vary, depending upon the portion of the brain affected. 

  • Track 22-1Behavior variant frontotemporal dementia
  • Track 22-2Primary progressive aphasia
  • Track 22-3Diagnosis of frontotemporal dementia
  • Track 22-4Causes and risks of frontotemporal dementia
  • Track 22-5Treatment of frontotemporal dementia

Semantic dementia, which has also been called "temporal variant FTD," accounts for 20% of FTD cases. Language difficulty, the predominant complaint of people with SD, is due to the disease damaging the left temporal lobe, an area critical for assigning meaning to words. The language deficit is not in producing speech but is a loss of the meaning, or semantics, of words.

Semantic Dementia is one of the three canonical clinical syndromes associated with front temporal lobar degeneration.

  • Track 23-1Mild semantic dementia
  • Track 23-2Moderate semantic dementia
  • Track 23-3Severe semantic dementia
  • Track 23-4Clinical features of semanic dementia
  • Track 23-5Causes of semantic dementia
  • Track 23-6Treatment of semantic dementia

Brain is an intangible conundrum which buries millions and millions of memories.

Entrepreneurship is the process of designing a new business, i.e. a startup company offering a product, process or service.

We are convinced that these new approaches to entrepreneurship research will have high impact and will lead to some of the most exciting and best publications in the years to come.

Bringing these new approaches together in one track will provide a forum for some of the best scholars in the field to join Vascular Dementia Conference 2016 and it will provide the audience with a look into the future of entrepreneurship research.

 

  • Track 24-1Simulation semantics
  • Track 24-2Cognitive science
  • Track 24-3Computational theory of mind
  • Track 24-4Next generation of entrepreneurs in neuroscience
  • Track 24-5Neuroscience and brain game
  • Track 24-6Neuromanagement
  • Track 24-7Neuro-industrial-engineering